We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients
News

Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients

Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients
News

Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients

Credit: iStock
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lopinavir is a drug against HIV, hydroxychloroquine is used to treat malaria and rheumatism. Until recently, both drugs were regarded as potential agents in the fight against the coronavirus SARS-CoV-2. A research group from the University of Basel and the University Hospital Basel has now discovered that the concentration of the two drugs in the lungs of Covid-19 patients is not sufficient to fight the virus.

In February 2020, a Covid-19 patient cohort was established at the University and the University Hospital in Basel to prospectively monitor a range of diagnostic means and potential treatments for Covid-19, including the off-label use of hydroxychloroquine and lopinavir/ritonavir.

A research group monitored lopinavir plasma levels in Covid-19 patients. “Considering that substantial inflammation was observed in these patients, and previous studies have shown the inhibition of drug metabolism by systemic inflammation, we had the rationale to investigate the effect of inflammation on lopinavir and hydroxychloroquine plasma levels,” states Professor Catia Marzolini, first author of the study and professor for experimental medicine at the University of Basel.

The authors included 92 patients in their study. Professor Parham Sendi, who is the co-leader of this study summarizes the main findings of the study as follows: First, lopinavir plasma levels were more than two to threefold higher than typically observed in HIV patients. Hydroxychloroquine levels were with normal range. Second, there was a significant correlation between the inflammation marker levels in the blood and lopinavir plasma levels. And third, when the inflammation was blocked with the Interleukin-6 inhibitor Tocilizumab, lopinavir plasma levels were significantly lower than the ones in patients without Tozulizumab treatment.

These results clearly indicate that drug metabolism enzymes (cytochrome P450 3A) are inhibited by systemic inflammation. “Caution is advised when prescribing CYP3A4 substrates such as Lopinavir/ritonavir or any other drug with a narrow therapeutic index to Covid-19 patients because of the risk of elevated drug levels and related toxicities,” the authors note.

Importantly, from the lopinavir and hydroxychloroquine concentrations in the plasma, the study group calculated the corresponding concentration in the lung compartment – the anatomic site of SARS-CoV-2 infection. The results strongly suggest that it is unlikely that both drugs reach sufficient concentrations to inhibit the virus replication in the lung. 

WHO accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms on 4 July 2020. Professor Manuel Battegay – the co-leader of this study and head of the Division of Infectious Diseases and Hospital Epidemiology at the University Hospital in Basel - mentioned that the results of this study provide important pharmacological and antiviral insights to the rationale of discontinuing the lopinavir/ritonavir arm. In fact, they explain why hydroxychloroquine and lopinavir are not effective against the SARS-CoV-2.

Reference: Marzolini, et al. (2020). Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. Antimicrobial Agents and Chemotherapy. DOI: 10.1128/AAC.01177-20

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement